Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 40

Sort by

Sort Order Select

Journal Articles

Cell Type-Specific Deregulation of Polypyrimidine Tract- Binding Proteins (PTBPs) Drive Aberrant Splicing in Multiple Myeloma (MM) and Acute Myeloid Leukemia (AML)

Sophia Adamia, PhD, Sigitas J Verselis, PhD, Teru Hideshima, MD PhD, Michael P. Chu, MD, Shruti Bhatt, PhD, David P. Steensma, MD, Daniel J Deangelo, Richard M. Stone, MD, Daniel G. Tenen, MD, Linda M. Pilarski, PhD, James D. Griffin, MD, Kenneth Anderson, MD

Blood (2018) 132 (Supplement 1): 3895.

https://doi.org/10.1182/blood-2018-99-118501

Published: 2018

Journal Articles

Treatment Patterns and Healthcare Resource Utilization in Patients with Relapsed/Refractory Acute Myeloid Leukemia and a Subset with IDH1-Mutation: A United States Medical Chart Review Study

James D. Griffin, MD, Mike Storm, MSc, Ken Wilhelm, MD, Audra Boscoe, PhD, Dendy Macaulay, PhD, Zheng-Yi Zhou, PhD, Elizabeth Faust, MBA/MPH, Claudia Cheung, MS

Blood (2018) 132 (Supplement 1): 5864.

https://doi.org/10.1182/blood-2018-99-116495

Published: 2018

Journal Articles

Treatment Patterns and Healthcare Resource Utilization (HRU) in Patients with Relapsed/Refractory (R/R) FLT3 -Mutated ( FLT3 mut ) and FLT3 -Wild Type ( FLT3 wt ) Acute Myeloid Leukemia (AML): A Multi-Country Medical Chart Study

James D. Griffin, MD, Manasee V Shah, MPH, Yan Song, PhD, Hongbo Yang, PhD

Blood (2018) 132 (Supplement 1): 4824.

https://doi.org/10.1182/blood-2018-99-110871

Published: 2018

Journal Articles

Treatment Patterns and Healthcare Resource Utilization in Patients with FLT3-Mut and FLT3-Wt Acute Myeloid Leukemia: A Multi-Country Medical Chart Study

James D. Griffin, MD, Hongbo Yang, PhD, Yan Song, PhD, David Kinrich, BSE, Cat N. Bui, PhD

Blood (2017) 130 (Supplement 1): 2186.

https://doi.org/10.1182/blood.V130.Suppl_1.2186.2186

Published: 2017

Journal Articles

FLT3 Splice Variant (FLT3Va) As a Potential Immunotherapeutic Target in Patients with Acute Myeloid Leukemia (AML)

Sophia Adamia, PhD, Jeffrey Nemeth, PhD, Shruti Bhatt, PhD, Sarah R Walker, Natalie I Voeks, William Lento, PhD, Ricardo M. Attar, Ilene Galinsky, MSN, ANPc, David A Frank, MD PhD, Martha Wadleigh, MD, Anthony Letai, MD PhD, David P. Steensma, MD, David M. Weinstock, MD, Daniel J. DeAngelo, MD PhD, David M. Dorfman, MD PhD, Richard M. Stone, MD, James D Griffin, MD

Blood (2016) 128 (22): 1681.

https://doi.org/10.1182/blood.V128.22.1681.1681

Published: 2016

Journal Articles

Inhibition of USP10 Induces Degradation of Oncogenic FLT3: A Novel Approach to Therapy of Leukemia

Sara Buhrlage, PhD, Ellen Weisberg, MD, Nathan Schauer, Jing Yang, PhD, Ilaria Lamberto, PhD, Laura Doherty, Atsushi Nonami, MDPhD, Amanda L. Christie, BS, David M. Weinstock, MD, Richard M. Stone, MD, Nathanael Gray, PhD, James D Griffin, MD

Blood (2016) 128 (22): 524.

https://doi.org/10.1182/blood.V128.22.524.524

Published: 2016

Journal Articles

Integrin-Linked Kinase a Novel Therapeutic Target for Acute and Chronic Myeloid Leukemia

Pilar De La Puente, PhD, Ellen Weisberg, MD, Atsushi Nonami, MDPhD, Micah John Luderer, BS, MS, Richard M. Stone, MD, Junia V. Melo, MD PhD, James D Griffin, MD, Abdel Kareem Azab, BPharm, PhD

Blood (2015) 126 (23): 3694.

https://doi.org/10.1182/blood.V126.23.3694.3694

Published: 2015

Journal Articles

Identification of Wee1 and IGF-1R As Novel Therapeutic Targets for Mutant RAS-Driven Acute Leukemia By Combinatory Chemical Screens

Atsushi Nonami, MDPhD, Chen Zhao, PhD, Liu Qingsong, PhD, Kristen Cowens, Amanda L. Christie, Yongfei Chen, Martin Sattler, PhD, Kwok-Kin Wang, MDPhD, Nathanael S. Gray, PhD, James D. Griffin, MD, Ellen L. Weisberg, PhD

Blood (2014) 124 (21): 3502.

https://doi.org/10.1182/blood.V124.21.3502.3502

Published: 2014

Journal Articles

IDH1 Splicing Alterations in Patients with AML and Their Relationship to Blood 2HG Levels

Sophia Adamia, PhD, Patricia Toniolo, PhDcandidate, Amir T. Fathi, MD, Ilene Galinsky, ANP, Suiyang Liu, Katharine Yen, Hyeryun Kim Kim, Dongwei Zhu, Straley Kim, Martha Wadleigh, MD, David P. Steensma, MD, Ibiayi Dagogo-Jack, MD, Daniel J. DeAngelo, MD PhD, James D. Griffin, MD, Richard M. Stone, MD

Blood (2014) 124 (21): 1060.

https://doi.org/10.1182/blood.V124.21.1060.1060

Published: 2014

Journal Articles

Aberrant Splicing In Patients With AML Is Associated With Over- Expression Of Specific Splicing Factors

Sophia Adamia, PhD, Christian Bach, Ph.D., Patrick M Pilarski, Martha Wadleigh, MD, David P. Steensma, MD, Gabriela Motyckova, MD, PhD, Daniel J. DeAngelo, MD, Ph.D, Richard M. Stone, MD, Daniel G. Tenen, MD, James D. Griffin, MD

Blood (2013) 122 (21): 3749.

https://doi.org/10.1182/blood.V122.21.3749.3749

Published: 2013

Journal Articles

Using Small Molecules To Identify Critical Signaling Pathways Of Mutant N-RAS In Acute Leukemia Cells

Atsushi Nonami, MD, PhD, Martin Sattler, PhD, Ellen L. Weisberg, PhD, Jianming Zhang, PhD, Qingsong Liu, PhD, Matthew Patricell, PhD, Hojong Yoon, Amanda L. Christie, B.S., Amy M. Sauer, Nancy Kohl, PhD, Andrew L. Kung, MD, PhD, Taebo Sim, PhD, Nathanael S. Gray, PhD, James D. Griffin, MD

Blood (2013) 122 (21): 169.

https://doi.org/10.1182/blood.V122.21.169.169

Published: 2013

Journal Articles

Small Molecule Activators Of AMPK Block The Glycogen Production Required For Transformation Of Myeloid Leukemia Cells

Haymanti Bhanot, PhD, Mamatha M. Reddy, PhD, Atsushi Nonami, MD, PhD, Ellen L. Weisberg, PhD, Kelly Xing, Sabrina K. Salgia, John M. Asara, PhD, Richard M. Stone, MD, James D. Griffin, MD, Martin Sattler, PhD

Blood (2013) 122 (21): 1479.

https://doi.org/10.1182/blood.V122.21.1479.1479

Published: 2013

Journal Articles

BCR-ABL Transformation Requires Glycogen Synthase 1 (GYS1) Expression for Cell Growth and Increased Glycogen Production

Mamatha M. Reddy, PhD, Anagha Deshpande, PhD, Atsushi Nonami, MD, PhD, Ellen L. Weisberg, PhD, Tirumala K. Chowdary, PhD, James D. Griffin, MD, Martin Sattler, PhD

Blood (2012) 120 (21): 1673.

https://doi.org/10.1182/blood.V120.21.1673.1673

Published: 2012

Journal Articles

Deciphering the Critical Pathways of Mutant N-RAS in AML Using Small Molecule Inhibitors.

Atsushi Nonami, MD, PhD, Martin Sattler, PhD, Ellen L. Weisberg, PhD, Liu Qingsong, PhD, Jianming Zhang, PhD, Guillaume Adelmant, PhD, Jarrod A Marto, PhD, Nancy Kohl, PhD, Andrew L. Kung, MD, PhD, Taebo Sim, PhD, Nathanael S Gray, PhD, James D. Griffin, MD

Blood (2012) 120 (21): 2455.

https://doi.org/10.1182/blood.V120.21.2455.2455

Published: 2012

Journal Articles

Comparison of Disease Outcomes for Patients with Chronic Myelogenous Leukemia in Chronic Phase Switched to Nilotinib or Dasatinib As Second-Line Therapy.

James D. Griffin, MD, Annie Guerin, MSc, Lei Chen, MD, PhD, Alexander R. Macalalad, MD, Jiayuan Luo, MSc, Eric Qiong Wu, PhD

Blood (2012) 120 (21): 2796.

https://doi.org/10.1182/blood.V120.21.2796.2796

Published: 2012

Journal Articles

Characteristics of Patients with Chronic Myelogenous Leukemia in Chronic Phase Switched to Nilotinib or Dasatinib As Second-Line Therapy

Alexander R. Macalalad, MD, Lei Chen, MD PhD, Annie Guerin, MSc, Jiayuan Luo, MSc, Eric Qiong Wu, PhD, James D. Griffin, MD

Blood (2012) 120 (21): 4447.

https://doi.org/10.1182/blood.V120.21.4447.4447

Published: 2012

Journal Articles

Comparison of Treatment Changes for Patients with Chronic Myelogenous Leukemia in Chronic Phase Switched From Imatinib to Nilotinib or Dasatinib As Second-Line Therapy

Alexander R. Macalalad, MD, Lei Chen, MD, PhD, Annie Guerin, MSc, Jiayuan Luo, MSc, Eric Qiong Wu, PhD, James D. Griffin, MD

Blood (2012) 120 (21): 4443.

https://doi.org/10.1182/blood.V120.21.4443.4443

Published: 2012

Journal Articles

Genome-Wide Aberrant Splicing in Patients with Acute Myelold Leukemia (AML) Is Associated with Altered Expression of Splicing Factors

Sophia Adamia, PhD, Hervé Avet-Loiseau, MD, PhD, Jana Jakubikova, Suzan Lazo-Kallanian, John Daley, PhD, Laurence Lode, Ph.D, Ilene Galinsky, ANP, Richard M. Stone, MD, James D. Griffin, MD

Blood (2012) 120 (21): 652.

https://doi.org/10.1182/blood.V120.21.652.652

Published: 2012

Journal Articles

A Phase I Trial of Escalating Dose of the Rapamycin Analog Everolimus in Combination with the Kinase Inhibitor Midostaurin in Patients (pts) with Relapsed, Refractory or Poor Prognosis Acute Myeloid Leukemia (AML)

Richard M. Stone, MD, Caitlin Driscoll, Ilene Galinsky, ANP, Martha Wadleigh, MD, David P. Steensma, MD, David Avigan, MD, Philip C. Amrein, MD, Suiyang Liu, James D. Griffin, MD, Steven L. McAfee, MD, Eyal C. Attar, MD, Karen K. Ballen, MD, Edward Fox, PhD, Daniel J. DeAngelo, MD, PhD

Blood (2012) 120 (21): 3627.

https://doi.org/10.1182/blood.V120.21.3627.3627

Published: 2012

Journal Articles

Potentiation of the Effects of Nilotinib by Combination with Plerixafor in a Mouse Model of BCR-ABL-Positive Residual Disease

Ellen L Weisberg, Ph.D., Paul W. Manley, Ph. D., Andrew L. Kung, MD, PhD, James D. Griffin, MD

Blood (2011) 118 (21): 2737.

https://doi.org/10.1182/blood.V118.21.2737.2737

Published: 2011

NARROW

Cell Type-Specific Deregulation of Polypyrimidine Tract- Binding Proteins (PTBPs) Drive Aberrant Splicing in Multiple Myeloma (MM) and Acute Myeloid Leukemia (AML)

Treatment Patterns and Healthcare Resource Utilization in Patients with Relapsed/Refractory Acute Myeloid Leukemia and a Subset with IDH1-Mutation: A United States Medical Chart Review Study

Treatment Patterns and Healthcare Resource Utilization (HRU) in Patients with Relapsed/Refractory (R/R) FLT3 -Mutated ( FLT3 mut ) and FLT3 -Wild Type ( FLT3 wt ) Acute Myeloid Leukemia (AML): A Multi-Country Medical Chart Study

Treatment Patterns and Healthcare Resource Utilization in Patients with FLT3-Mut and FLT3-Wt Acute Myeloid Leukemia: A Multi-Country Medical Chart Study

FLT3 Splice Variant (FLT3Va) As a Potential Immunotherapeutic Target in Patients with Acute Myeloid Leukemia (AML)

Inhibition of USP10 Induces Degradation of Oncogenic FLT3: A Novel Approach to Therapy of Leukemia

Integrin-Linked Kinase a Novel Therapeutic Target for Acute and Chronic Myeloid Leukemia

Identification of Wee1 and IGF-1R As Novel Therapeutic Targets for Mutant RAS-Driven Acute Leukemia By Combinatory Chemical Screens

IDH1 Splicing Alterations in Patients with AML and Their Relationship to Blood 2HG Levels

Aberrant Splicing In Patients With AML Is Associated With Over- Expression Of Specific Splicing Factors

Using Small Molecules To Identify Critical Signaling Pathways Of Mutant N-RAS In Acute Leukemia Cells

Small Molecule Activators Of AMPK Block The Glycogen Production Required For Transformation Of Myeloid Leukemia Cells

BCR-ABL Transformation Requires Glycogen Synthase 1 (GYS1) Expression for Cell Growth and Increased Glycogen Production

Deciphering the Critical Pathways of Mutant N-RAS in AML Using Small Molecule Inhibitors.

Comparison of Disease Outcomes for Patients with Chronic Myelogenous Leukemia in Chronic Phase Switched to Nilotinib or Dasatinib As Second-Line Therapy.

Characteristics of Patients with Chronic Myelogenous Leukemia in Chronic Phase Switched to Nilotinib or Dasatinib As Second-Line Therapy

Comparison of Treatment Changes for Patients with Chronic Myelogenous Leukemia in Chronic Phase Switched From Imatinib to Nilotinib or Dasatinib As Second-Line Therapy

Genome-Wide Aberrant Splicing in Patients with Acute Myelold Leukemia (AML) Is Associated with Altered Expression of Splicing Factors

A Phase I Trial of Escalating Dose of the Rapamycin Analog Everolimus in Combination with the Kinase Inhibitor Midostaurin in Patients (pts) with Relapsed, Refractory or Poor Prognosis Acute Myeloid Leukemia (AML)

Potentiation of the Effects of Nilotinib by Combination with Plerixafor in a Mouse Model of BCR-ABL-Positive Residual Disease

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only